secwatch.observer — SEC 8-K summary
======================================

Issuer:     Wave Life Sciences Ltd. (WVE)
CIK:        0001631574
Form:       8-K
Filed at:   2023-09-28T23:59:59+00:00
Accession:  0001193125-23-245724
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Wave Life Sciences unveils INHBE siRNA for obesity, targets 5 new clinical candidates by 2025
--------------------------------------------------------------------------------

- New GalNAc-siRNA program targeting INHBE for metabolic disorders including obesity; expects clinical candidate in 4Q 2024.
- INHBE knockdown of 62% in DIO mice led to 16% lower body weight vs control at 5 weeks; visceral fat reduction in 8-week study.
- WVE-006 for AATD: dosing in healthy volunteers expected 4Q 2023; proof-of-mechanism data in AATD patients in 2024.
- Plans to select five new clinical candidates by year-end 2025, spanning RNA editing (correction and upregulation) and siRNA.
- WVE-N531 in DMD: muscle biopsy data show uptake in satellite cells after 3 doses; data from registrational Phase 2 (FORWARD-53) expected 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1631574/000119312523245724/0001193125-23-245724-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1631574/000119312523245724/d537767d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-245724

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer